BioCentury
ARTICLE | Clinical News

CaPTHymone: Phase I/II started

December 3, 2007 8:00 AM UTC

BNE began a single-blind, crossover, Australian Phase I/II trial in 8 healthy post-menopausal women to compare 400 and 800 µg doses of oral CaPTHymone. ...